Clinical Trials Logo

Clinical Trial Summary

This is a single center Phase 1, placebo-controlled, randomized, double blind, first-in-human (FIH), sequential single ascending dose (SAD) study.

Clinical Trial Description

GBS-101 is a single center Phase 1, placebo-controlled, randomized, double blind, first-in-human (FIH), sequential single ascending dose (SAD) study to evaluate the safety, tolerability and PK of GV101 in healthy subjects. 8 healthy subjects wills be enrolled in each of 7 cohorts of the study (50 mg (tablet), 100 mg (tablet), 200 mg (tablet), 400 mg (tablet), 400 mg (liquid), 800 mg (liquid), 1600 mg (liquid). Participants will be randomized in a 3:1 ratio, 1:1 for 2 sentinel subjects and 5: 1 GV101 drug to matching placebo thereafter. Subjects in each cohort will receive a single oral dose of GV101 or matching placebo under fasting conditions. A staggered schedule will be used for each dose level, where 2 sentinel subjects (1 active and 1 placebo) will be dosed first, with the remaining 6 subjects (5 active and 1 placebo) dosed at least 24 hours after the sentinel subjects. This study of GV101 will provide safety, tolerability, and plasma pharmacokinetic data in healthy individuals. The PK component will characterize the PK of GV101 to inform dosing and may help to correlate exposures treatment-related AEs. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05068947
Study type Interventional
Source Graviton Bioscience Corporation
Contact Amy Melsaether, MD
Phone 3107705010
Email [email protected]
Status Recruiting
Phase Phase 1
Start date September 10, 2021
Completion date January 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04485481 - Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers Phase 1
Completed NCT03473236 - Phase 1A Safety Trial of Inhaled PK10571 (GB002) Phase 1
Not yet recruiting NCT03683953 - The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells Phase 1
Completed NCT04335045 - Phase I Study of PH100 (Ecklonia Cava Phlorotannins) Phase 1
Not yet recruiting NCT05041699 - PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel Phase 1/Phase 2
Recruiting NCT05037227 - Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
Not yet recruiting NCT04499482 - Safety and Tolerability of Soy Fiber N/A
Active, not recruiting NCT03177746 - The Safety of Dapoxetine/Tadalafil Combination Therapy Phase 4
Recruiting NCT04573049 - The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement Phase 4
Completed NCT04188821 - Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander N/A
Completed NCT03667430 - Safety Evaluation of Porous Silica in Men N/A
Not yet recruiting NCT04622943 - An Interactive Web Platform to Teach Children Hunting, Shooting and Firearms Safety N/A
Completed NCT03141905 - Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease N/A
Recruiting NCT03791372 - Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy Phase 1
Not yet recruiting NCT04774900 - Standardization of Ambulance Equipment
Not yet recruiting NCT04759066 - The HEALiX™ Intubated Patient (IP) Pilot Study N/A
Active, not recruiting NCT04690725 - TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss Phase 1/Phase 2
Active, not recruiting NCT04002440 - Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight N/A
Terminated NCT03585192 - Safety of Immediate Skin-to-Skin Contact After Vaginal Birth in Vigorous Late-Preterm Neonates N/A
Completed NCT03157414 - Empagliflozin in Renal Transplant Recipients Phase 4